Tumor-associated and immunochemotherapydependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients

OncoImmunology

Volumn 4, Issue 3, 2015, Pages 1-12

  Cox, M Christina ^a   Battella, Simone ^b   La Scaleia, Raffaella ^b   Pelliccia, Sabrina ^a   Di Napoli, Arianna ^c   Porzia, Alessandra ^d   Cecere, Francesca ^d   Alma, Eleonora ^a   Zingoni, Alessandra ^d   Mainiero, Fabrizio ^b   Ruco, Luigi ^c   Monarca, Bruno ^a   Santoni, Angela ^c,d   Palmieri, Gabriella ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ADCC; CD16; DLBCL; NK cells; NKG2D; R CHOP immunochemotherapy; Rituximab

Indexed keywords

GAMMA INTERFERON; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOTOXICITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY;

EID: 84945550230     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.990773     Document Type: Article

References (73)

1. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76:2421-38; PMID:2265240
2. Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol 2014; 26:161-72; PMID:24618042; http://dx.doi.org/10.1016/j.smim.2014.02.002
3. Chretien AS, Le Roy A, Vey N, Prebet T, Blaise D, Fauriat C, Olive D. Cancer-induced alterations of NKmediated target recognition: current and investigational pharmacological strategies aiming at restoring NKmediated anti-tumor activity. Front Immunol 2014; 5:122; PMID:24715892; http://dx.doi.org/10.3389/fimmu.2014.00122
4. The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997; 89:3909-18; PMID:9166827
5. Pasqualucci L. The genetic basis of diffuse large B-cell lymphoma. Curr Opin Hematol 2013; 20:336-44; PMID:23673341; http://dx.doi.org/10.1097/MOH.0b013e3283623d7f
6. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013; 87:146-71; PMID:23375551; http://dx.doi.org/10.1016/j.critrevonc.2012.12.009
7. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Annu Rev Med 2008; 59:237-50; PMID:18186705; http://dx.doi.org/10.1146/annurev.med.59.060906.220345
8. Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res 2012; 2:676-90; PMID:23226614
9. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44:3823-37; PMID:17768100; http://dx.doi.org/10.1016/j.molimm.2007.06.151
10. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47:115-23; PMID:20350658; http://dx.doi.org/10.1053/j.seminhematol.2010.01.011
11. Dall’Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G. Rituximabdependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004; 64:4664-69; PMID:15231679; http://dx.doi.org/10.1158/0008-5472.CAN-03-2862
12. Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, Marquis D, Ondek B, Wooldridge JE, Smith BJ, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006; 108:2648-54; PMID:16825493; http://dx.doi.org/10.1182/blood-2006-04-020057
13. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma} RIIIa-158 V/V and V/F polymorphism. Blood 2007; 110:2561-64; PMID:17475906; http://dx.doi.org/10.1182/blood-2007-01-070656
14. Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, Weiner GJ. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 2011; 118:3347-49; PMID:21768303; http://dx.doi.org/10.1182/blood-2011-05-351411
15. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-58; PMID:11806974; http://dx.doi.org/10.1182/blood.V99.3.754
16. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006; 108:2720-25; PMID:16609067; http://dx.doi.org/10.1182/blood-2006-01-009480
17. de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010; 70:3209-17; PMID:20354182; http://dx.doi.org/10.1158/0008-5472.CAN-09-4109
18. Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 2013; 4:76; PMID:23543707; http://dx.doi.org/10.3389/fimmu.2013.00076
19. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47:187-376; PMID:2683611; http://dx.doi.org/10.1016/S0065-2776(08)60664-1
20. Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 2007; 7:703-14; PMID:17717540; http://dx.doi.org/10.1038/nri2154
21. Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8⁺ T cells. Nat Rev Immunol 2011; 11:645-57; PMID:21869816; http://dx.doi.org/10.1038/nri3044
22. Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural killer cell development. Trends Immunol 2013; 34:573-82; PMID:24055329; http://dx.doi.org/10.1016/j.it.2013.07.005
23. Bottino C, Moretta L, Moretta A. NK cell activating receptors and tumor recognition in humans. Curr Top Microbiol Immunol 2006; 298:175-82; PMID:16323416
24. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9:495-502; PMID:18425106; http://dx.doi.org/10.1038/ni1581
25. Long EO, Sik Kim H, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013; 31:227-58; PMID:23516982; http://dx.doi.org/10.1146/annurev-immunol-020711-075005
26. Kruse PH, Matta J, Ugolini S, Vivier E. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol 2014; 92:221-9; PMID:24366519; http://dx.doi.org/10.1038/icb.2013.98
27. Trinchieri G, Valiante N. Receptors for the Fc fragment of IgG on natural killer cells. Nat Immun 1993; 12:218-34.
28. Perussia B. Fc receptors on natural killer cells. Curr Top Microbiol Immunol 1998; 230:63-88; PMID:9586351
29. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27:5944-58; PMID:18836475; http://dx.doi.org/10.1038/onc.2008.272
30. Burgess SJ, Maasho K, Masilamani M, Narayanan S, Borrego F, Coligan JE. The NKG2D receptor: immunobiology and clinical implications. Immunol Res 2008; 40:18-34; PMID:18193361; http://dx.doi.org/10.1007/s12026-007-0060-9
31. El-Gazzar A, Groh V, Spies T. Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J Immunol 2013; 191:1509-15; PMID:23913973; http://dx.doi.org/10.4049/jimmunol.1301071
32. Le Bert N, Gasser S. Advances in NKG2D ligand recognition and responses by NK cells. Immunol Cell Biol 2014; 92:230-6; PMID:24445601; http://dx.doi.org/10.1038/icb.2013.111
33. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31:413-41; PMID:23298206; http://dx.doi.org/10.1146/annurevimmunol-032712-095951
34. Wiemann K, Mittrücker HW, Feger U, Welte SA, Yokoyama WM, Spies T, Rammensee HG, Steinle A. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 2005; 175:720-9; PMID:16002667; http://dx.doi.org/10.4049/jimmunol.175.2.720
35. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28:571-80; PMID:18394936; http://dx.doi.org/10.1016/j.immuni.2008.02.016
36. Grzywacz B, Kataria N, Verneris MR. CD56(dim) CD16(C) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 2007; 21:356-9; PMID:17251901; http://dx.doi.org/10.1038/sj.leu.2404499
37. Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, Luo X, Cooley S, Verneris M, Walcheck B, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013; 121:3599-608; PMID:23487023; http://dx.doi.org/10.1182/blood-2012-04-425397
38. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6:836-48; PMID:17063185; http://dx.doi.org/10.1038/nri1961
39. Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, Cardelli P, Montefusco E, Conte E, Monarca B, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 2008; 49; 1745-51; PMID:18798109; http://dx.doi.org/10.1080/10428190802226425
40. Watanabe R, Tomita N, Itabashi M, Ishibashi D, Yamamoto E, Koyama S, Miyashita K, Takahashi H, Nakajima Y, Hattori Y, et al. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol 2014; 92:204-10; PMID:24283206; http://dx.doi.org/10.1111/ejh.12221
41. Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, et al. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 2014; 55:2728-2738; PMID:24547705; http://dx.doi.org/10.1038/sj.bmt.1705565
42. Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P, Rabian C, Casasnovas O, Labalette M, et al. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2–3 diffuse large B-cell lymphoma. Ann Oncol 2007; 18:1209-15; PMID:17496307; http://dx.doi.org/10.1093/annonc/mdm110
43. Danielou-Lazareth A, Henry G, Geromin D, Khaznadar Z, Briere J, Tamouza R, Cayuela JM, Thieblemont C, Toubert A, Dulphy N. At diagnosis, diffuse large Bcell lymphoma patients show impaired rituximabmediated NK-cell cytotoxicity. Eur J Immunol 2013; 43:1383-88; PMID:23400905; http://dx.doi.org/10.1002/eji.201242733
44. Fischer L, Penack O, Gentilini C, Nogai A, Muessig A, Thiel E, Uharek L. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol 2006; 34:753-9; PMID:16728280; http://dx.doi.org/10.1016/j.exphem.2006.02.015
45. Inagaki A, Ishida T, Yano H, Ishii T, Kusumoto S, Ito A, Ri M, Mori F, Ding J, Komatsu H, et al. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. Int J Cancer 2009; 125:212-21; PMID:19358282; http://dx.doi.org/10.1002/ijc.24351
46. Deguine J, Breart B, Lemaıtre F, Bousso P. Cutting Edge: Tumor-Targeting Antibodies Enhance NKG2DMediated NK Cell Cytotoxicity by Stabilizing NK Cell–Tumor Cell Interactions. J Immunol 2012; 189:5493-97; PMID:23183896; http://dx.doi.org/10.4049/jimmunol.1202065
47. Kuriyama Y, Nakano M, Kawanishi Y, Iwase O, Aizawa S, Toyama K. Cytotoxic lymphocytes in the peripheral blood of patients with B cell lymphomas. Leukemia 1995; 9:2123-6; PMID:8609727
48. Tursz T, Dokhelar MC, Lipinski M, Amiel JL. Low natural killer cell activity in patients with malignant lymphoma. Cancer 1982; 50:2333-5; PMID:6958348; http://dx.doi.org/10.1002/1097-0142(19821201)50:11%3c2333::AID-CNCR2820501119%3e3.0.CO;2-W
49. Ono K. Clinical significance of natural killing activity in patients with advanced lymphoma. J Clin Immunol 1998; 18:132-41; PMID:9533657; http://dx.doi.org/10.1023/A:1023298917191
50. Kim JK, Chung JS, Shin HJ, Song MK, Yi JW, Shin DH, Lee DS, Baek SM. Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood Res 2014; 49:162-9; PMID:25325035; http://dx.doi.org/10.5045/br.2014.49.3.162
51. Markasz L, Stuber G, Vanherberghen B, Flaberg E, Olah E, Carbone E, Eksborg S, Klein E, Skribek H, Szekely L. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Mol Cancer Ther 2007; 6:644-54; PMID:17308061; http://dx.doi.org/10.1158/1535-7163.MCT-06-0358
52. Katz P, Zaytoun AM, Lee JH Jr. Mechanisms of human cell-mediated cytotoxicity. III. dependence of natural killing on microtubule and microfilament integrity. J Immunol 1982; 129:2816-25; PMID:6890568
53. Riccardi C, Barlozzari T, Santoni A, Herberman RB, Cesarini C. Transfer to cyclophosphamide-treated mice of natural killer (NK) cells and in vivo natural reactivity against tumors. J Immunol 1981; 126:1284-89; PMID:7204966
54. Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007; 62:43-52; PMID:17287129; http://dx.doi.org/10.1016/j.critrevonc.2006.09.004
55. Arpon DR, Gandhi MK, Martin JH. A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug. Br J Clin Pharmacol 2014; 78:274-81; PMID:24433338; http://dx.doi.org/10.1111/bcp.12318
56. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002; 62:6178-86; PMID:12414645
57. G Mentlik, James A, Cohen AD, Campbell KS. Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol 2013; 4:1-12; PMID:23355837
58. Kellner C, Hallack D, Glorius P, Staudinger M, Mohseni Nodehi S, de Weers M, van de Winkel JG, Parren PW, Stauch M, et al. Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia 2012; 26:830-4; PMID:22005785; http://dx.doi.org/10.1038/leu.2011.288
59. Zhang Y, Wallace DL, de Lara CM, Ghattas H, Asquith B, Worth A, Griffin GE, Taylor GP, Tough DF, Beverley PC, et al. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 2007; 121:258-65; PMID:17346281; http://dx.doi.org/10.1111/j.1365-2567.2007.02573.x
60. Charbonneau B, Maurer MJ, Ansell SM, Slager SL, Fredericksen ZS, Ziesmer SC, Macon WR, Habermann TM, Witzig TE, Link BK, et al. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based casecontrol study. Cytokine 2012; 60:882-9; PMID:23010502; http://dx.doi.org/10.1016/j.cyto.2012.08.028
61. McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 2014; 16:717-27; PMID:25082194; http://dx.doi.org/10.1038/ncb3015
62. Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hänel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, et al. Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann Oncol 2014; 25:1800-06; PMID:24928834; http://dx.doi.org/10.1093/annonc/mdu208
63. Lindorfer MA, Wiestner A, Zent CS, Taylor RP. Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?. Oncoimmunology 2012; 1:959-61; PMID:23162771; http://dx.doi.org/10.4161/onci.20368
64. Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, Lucas J, Denis-Mize K, Tong B, Navis D, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin’s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004; 10:2253-64; PMID:15073100; http://dx.doi.org/10.1158/1078-0432.CCR-1087-3
65. Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, et al. Combination immunotherapy of B-cell non-Hodgkin’s lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res 2004; 10:6101-10; PMID:15447996; http://dx.doi.org/10.1158/1078-0432.CCR-04-0525
66. Ysebaert L, Gross E, Kühlein E, Blanc A, Corre J, Fournié JJ, Laurent G, Quillet-Mary A. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia 2010; 24:1310-16; PMID:20463751; http://dx.doi.org/10.1038/leu.2010.89
67. Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, Fuseri N, Bonnafous C, Czerwinski D, Rajapaksa A, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2014; 123:678-86; PMID:24326534; http://dx.doi.org/10.1182/blood-2013-08-519199
68. Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung SH, Zhou L, Hsu K, Czuczman MS, Cheson B, Kaplan L, et al. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2014; 2:878-89; PMID:24958280; http://dx.doi.org/10.1158/2326-6066.CIR-13-0158
69. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102:596-602; PMID:2580468; http://dx.doi.org/10.7326/0003-4819-102-5-596
70. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-86; PMID:17242396; http://dx.doi.org/10.1200/JCO.2006.09.2403
71. Palmieri G, Serra A, De Maria R, Gismondi A, Milella M, Piccoli M, Frati L, Santoni A. Cross-linking of alpha 4 beta 1 and alpha 5 beta 1 fibronectin receptors enhances natural killer cell cytotoxic activity. J Immunol 1995; 155:5314-22; PMID:7594545
72. Cerboni C, Ardolino M, Santoni A, Zingoni A. Detuning CD8C T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells. Blood 2009; 113:2955-64; PMID:19124832; http://dx.doi.org/10.1182/blood-2008-06-165944
73. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66:2520-6; PMID:16510567; http://dx.doi.org/10.1158/0008-5472.CAN-05-2520